Enlimomab Biosimilar - Research Grade

Human

ICAM1

>1mg/ml

IgG2a - nd

CHO Cells

Anti-ICAM-1 (15.2) In Vivo Antibody - Low Endotoxin (ICH1027), Bersanlimab Biosimilar - Research Grade (ICH5394)

https://www.imgt.org/mAb-DB/

ICH3002

P05362

Blue ice

This is a research-grade, unconjugated non-therapeutic recombinant analog of enlimomab, an anti-ICAM-1 (CD54) antibody, produced for research use only and not intended for human or veterinary use. It is built around the same human target, ICAM1 (UniProt P05362), so it can serve as a well-characterized binding reagent for studying ICAM-1 biology and for benchmarking ICAM-1-directed programs. Typical research applications include use as a positive or isotype-matched control, a blocking/neutralizing tool in adhesion and leukocyte-migration assays, a capture or detection reagent, and a reference standard in in-vitro and preclinical characterization work. It is offered at research grade with low endotoxin (generally under 1 EU/mg, with ultra-low-endotoxin options under 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support assay development, screening cascades, and larger preclinical studies. Because it is supplied unconjugated, it can be paired with downstream labeling or conjugation chemistries for ADC-development workflows, detection, or immobilization as required by the end user. ICAM-1 (intercellular adhesion molecule 1, CD54; gene ICAM1, UniProt P05362) is a type I transmembrane glycoprotein of the immunoglobulin superfamily, comprising five extracellular Ig-like domains, a transmembrane region, and a short cytoplasmic tail. It is expressed at low basal levels on endothelial cells, epithelial cells, and leukocytes and is strongly upregulated by inflammatory cytokines such as TNF, IL-1, and IFN-gamma. ICAM-1 is a principal counter-receptor for the beta-2 integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18), mediating firm adhesion, leukocyte transendothelial migration, and immunological-synapse formation. It also serves as the cellular receptor for human rhinovirus and for Plasmodium falciparum-infected erythrocytes. Through these interactions ICAM-1 contributes to inflammation, immune-cell trafficking, and tissue injury, making it a long-standing target in ischemia-reperfusion, transplantation, and autoimmune research.

Major group rhinovirus receptor, Intercellular adhesion molecule 1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Enlimomab biosimilar available in bulk or gram quantities?

A: Yes — the Enlimomab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Enlimomab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Enlimomab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Enlimomab that binds ICAM1.